Crude Incidence of Candidemia 8.7 Per 100,000 in 2012 to 2016Last Updated: September 30, 2019. The crude incidence of candidemia was 8.7 per 100,000 population across four states in 2012 to 2016, according to a surveillance summary published in the Sept. 27 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
MONDAY, Sept. 30, 2019 (HealthDay News) -- The crude incidence of candidemia was 8.7 per 100,000 population across four states in 2012 to 2016, according to a surveillance summary published in the Sept. 27 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Mitsuru Toda, Ph.D., from the CDC in Atlanta, and colleagues describe the incidence of candidemia based on active surveillance of culture-confirmed cases in 22 counties in four states (Georgia, Maryland, Oregon, and Tennessee) from 2012 to 2016.
The researchers identified 3,492 cases of candidemia across all sites and surveillance years. The crude incidence averaged across sites and years was 8.7 per 100,000 population. The highest and lowest crude annual incidence rates were seen in Maryland and Oregon (14.1 and 4.0 per 100,000 population, respectively). Adults aged ≥65 years had the highest crude annual incidence (25.5 per 100,000 population), followed by infants aged <1 year (15.8). Men had a higher crude annual incidence than women (9.4 versus 8.0), and incidence was higher among blacks than nonblacks (13.7 versus 5.8). Overall, one-third of cases occurred in patients who had undergone a surgical procedure in the previous 90 days, while 77 and 73 percent, respectively, occurred in patients who had received systemic antibiotics in the previous 14 days and in patients who had had a central venous catheter in place within two days before diagnosis. The all-cause, in-hospital case-fatality ratio was 25 percent.
"Ongoing surveillance efforts are expected to improve the development of treatment and prevention efforts," the authors write.
Two authors disclosed financial ties to the pharmaceutical industry.
|Previous: Rivaroxaban Cuts Recurrent Blood Clots in Obese Patients||Next: September 2019 Briefing - Allergy|
Reader comments on this article are listed below. Review our comments policy.